Carregant...
The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox
The novel Hsp90 inhibitor XL888 is undergoing clinical investigation for use in conjunction with the RAF inhibitor vemurafenib to treat unresectable melanoma. The addition of XL888 to current regimens may serve an additional purpose by blocking the RAF inhibitor paradox. Such activity could reduce a...
Guardat en:
| Publicat a: | J Invest Dermatol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4568562/ https://ncbi.nlm.nih.gov/pubmed/26358385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jid.2015.239 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|